Kerbrat P, Héron J F, Guastalla J P, Lhomme C, Goupil A, Toussaint C, Rey A, Chazard M, Lenaz L, George M
Centre Eugène-Marquis, Rennes, France.
Bull Cancer. 1991;78(12):1133-7.
Thirty female patients with ovarian cancer of poor prognosis were included in a chemotherapy trial using high dose IV carboplatin--800 mg/m2 every 5 weeks. The subjects had three to six cycles prior to second laparotomy. Twenty-eight patients were assessable. There was no neurological, auditory or renal toxicity. Limiting toxicity was haematological, the mean neutrophil count was less than 650 mm3 and the mean platelet count less than 30,000/mm3. No death occurred from toxicity. The clinical response rate was 67%, and the surgical response rate 53.5%, with 15% complete histological responses. Survival at 18 months is 36%. A trial concerning 36 patients treated with an association of carboplatin at the same dose combined with cyclophosphamide has just been completed and the results are being analyzed.
30名预后较差的卵巢癌女性患者被纳入一项使用高剂量静脉注射卡铂（每5周800mg/m²）的化疗试验。这些受试者在第二次剖腹手术前接受了三到六个周期的治疗。28名患者可进行评估。未出现神经、听觉或肾脏毒性。限制毒性为血液学毒性，平均中性粒细胞计数低于650/mm³，平均血小板计数低于30,000/mm³。无患者因毒性死亡。临床缓解率为67%，手术缓解率为53.5%，完全组织学缓解率为15%。18个月时的生存率为36%。一项关于36名患者使用相同剂量卡铂联合环磷酰胺治疗的试验刚刚完成，结果正在分析中。
